Oligonucleotide Synthesis Market
Oligonucleotide Synthesis Market by Offerings (Synthesis products [Consumables, Equipment], Synthesized Oligos (Type [DNA, RNA], Oligo-based Drugs (Type [ASO, siRNA), Therapy Area [Rare Diseases, Neurology, Oncology], Competition - Global Forecast to 2031
OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global oligonucleotide synthesis market is projected to grow from USD 14.64 billion in 2026 to USD 32.72 billion by 2031, at a CAGR of 17.4% during the forecast period. The market was valued at USD 11.66 billion in 2025. The major drivers of this market's growth include rapid clinical advances in RNA-based therapeutics, the widespread adoption of high-throughput CRISPR gene-editing screening libraries, the accelerating commercial scale-up of next-generation sequencing (NGS) diagnostics, and a significant influx of venture capital into disruptive enzymatic DNA synthesis platforms.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 11.66 Billion
Current Market Size (2026): USD 14.64 Billion
Forecast Market Size (2031): USD 32.72 Billion
CAGR (2026–2031): 17.4% -
SEGMENT LEADERSHIP:
Regional Leader: North America dominated the global oligonucleotide synthesis market in 2025.
Product Leader: Oligonucleotide-based drugs accounted for approximately 71.5% of the market in 2025.
Type Leader: Reagents & consumables accounted for approximately 92.1% of the oligonucleotide synthesis products market in 2025.
End User Leader: Specialty clinics accounted for approximately 44.7% of the market in 2025. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Leading companies in the oligonucleotide-based drugs market include Biogen, Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Novartis AG, while key players in the oligonucleotide synthesis products market include Danaher Corporation, Thermo Fisher Scientific Inc., and Merck KGaA.
Emerging companies such as Biolegio B.V. (Netherlands), Biolytic Lab Performance, Inc. (US), and Bio-Synthesis, Inc. (US) are rapidly expanding their presence by commercializing oligonucleotide synthesis products, synthesizers, and synthesized oligonucleotides.
The oligonucleotide synthesis market is growing steadily, driven by rising demand for therapeutic oligos (siRNA, ASO, mRNA adapters, CRISPR guides) and for clinical-grade GMP manufacturing. Growth is also fueled by routine use in qPCR/NGS library prep, companion diagnostics, and synthetic biology (gene circuits, DNA data storage, pooled screens). As programs advance from research to IND/BLA, buyers prioritize fast turnaround, high purity, and scalable QC (HPLC/UPLC, LC–MS).
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The fundamental shift from chemical small-molecules to advanced biotechnology therapies is significantly disrupting the oligonucleotide synthesis market. Over the forecast period from 2026 to 2031, traditional synthesis boundaries are increasingly dissolving as high-growth therapeutic areas—specifically oncology, precision neurology, and cardiovascular diseases—necessitate highly complex, long-chain oligonucleotides. This development is inducing substantial disruptions across related biological sectors: next-generation gene therapies are requiring custom-engineered single-guide RNAs, metagenomic sequencing is compelling the production of extensive parallel custom libraries, and mRNA-based therapeutic vaccines are scaling to commercial volumes. Consequently, synthesis providers must strategically transition from legacy laboratory-scale chemistries to high-throughput platforms capable of supporting these diverse macromolecular pipelines.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Increasing use of synthesized oligos in therapeutic & diagnostic applications
-
Growing government investments in life science research and synthetic biology
Level
-
Complexities associated with therapeutic oligonucleotides
Level
-
Increasing R&D investments by key players in emerging economies
Level
-
Lack of standard regulations
-
Delivery of oligonucleotide drugs to specific targets
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing use of synthesized oligos in therapeutic & diagnostic applications
The primary driver of market expansion through 2031 is the accelerating therapeutic and diagnostic shift toward high-complexity nucleic acid modalities. The broadening clinical validation of oligonucleotide-based candidates for highly prevalent neurological conditions and orphan indications has spurred a wave of global regulatory approvals, anchoring long-term market confidence. This expanding commercial portfolio is further bolstered by an aggressive, multi-indication clinical pipeline advancing into personalized oncology and metabolic diseases. Furthermore, traditional diagnostic paradigms are being disrupted by the integration of ultra-pure, high-throughput oligonucleotides into next-generation molecular diagnostics, microarrays, and precision genetic testing platforms.
Restraint: Complexities associated with therapeutic oligonucleotides
The primary market restraint through 2031 is the high technical difficulty of ensuring sequence consistency and structural stability. As synthesis length increases to create more complex genetic therapies, it becomes harder to prevent length-related mutations and to handle large amounts of toxic waste during purification. This results in a higher environmental impact and greater material waste, leading to stricter regulations and sustainability concerns that increase production costs for custom sequences.
Opportunity: Increasing R&D investments by key players in emerging economies
Massive growth opportunities are emerging between 2026 and 2031, driven by substantial life science infrastructure spending across emerging economies, particularly in the Asia-Pacific and Latin America regions. Tier-1 players are leveraging these regions to build clinical networks and local bio-clusters, supported by expanding biotechnology frameworks and cost-effective manufacturing capabilities. Concurrently, the operational commercialization of enzyme-mediated synthesis platforms offers a lucrative avenue for rapid, reagent-free production of ultra-long DNA and RNA sequences.
Challenge: Lack of standard regulations and delivery of oligonucleotide drugs
The most significant operational challenge remains the severe bottleneck in intracellular targeted delivery and the fragmented international regulatory landscape. Oligonucleotide therapies face substantial physiological barriers, requiring highly advanced lipid nanoparticle (LNP) and GalNAc conjugation technologies to safely cross cell membranes without triggering adverse immune reactions. This biological targeting hurdle is further compounded by the complete absence of unified cross-border standards for clinical-grade nucleic acid therapeutic approvals.
OLIGONUCLEOTIDE SYNTHESIS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Deployed high-fidelity single-stranded custom oligonucleotide pools (oPools Oligo Pools) to build massive parallel sequence variations for cell line development and high-throughput CRISPR screening libraries | Delivered industry-leading low error rates under 1 in 2,000 bases |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The oligonucleotide synthesis market operates within a highly interconnected, multi-tiered commercial value chain. The foundation comprises upstream instrumentation and reagent suppliers that provide the specialized chemistries and automated hardware required for strand assembly. In the midstream sector, pharmaceutical companies, biotechnology firms, and specialized CDMOs use these technologies to manufacture custom nucleic acid therapeutics, diagnostic arrays, and screening libraries. The downstream tier comprises hospitals, clinical research networks, and diagnostic laboratories that deploy these finished molecular tools in patient care. This entire ecosystem is governed by strict regulatory frameworks that mandate rigorous quality assurance, batch uniformity, and environmental compliance across all operational tiers.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Oligonucleotide Synthesis Market, By Offering
In 2025, the oligonucleotide-based drugs segment maintained its dominant position as the largest and fastest-growing segment in the market. The primary factors driving this sustained expansion include an accelerating rate of global regulatory approvals for novel nucleic acid therapies and a surge in clinical research targeting rare diseases. Furthermore, the market is experiencing a significant strategic shift toward developing innovative oligonucleotide-based therapeutics for high-prevalence, common indications such as cardiovascular disorders, metabolic diseases, and oncology.
Oligonucleotide Synthesis Products Market, By Application
In 2025, the therapeutic applications segment held the largest share of the oligonucleotide synthesis products market, driven by expanding clinical and commercial pipelines for oligonucleotide medicines, which require scalable and GMP-compatible synthesis and purification technologies. Growth is also supported by the recurring consumption of phosphoramidites, solid supports, activators, solvents, purification columns, filters, and other materials in every therapeutic-oligo manufacturing batch.
Oligonucleotide -based drugs Market, By End User
In 2025, the specialty clinics segment maintained the largest share of the oligonucleotide-based drugs market, driven by the expansion of specialized in-house molecular pharmacy networks and advanced genetic treatment centers within major healthcare systems.
REGION
North America to be fastest-growing region in overall global oligonucleotide synthesis market during forecast period
The North American oligonucleotide synthesis market is maintaining a commanding compound annual growth rate (CAGR), primarily propelled by the expanding development of oligo-based pharmaceuticals, an assertive wave of domestic mergers and acquisitions, and multi-million dollar capacity expansions within Contract Development and Manufacturing Organizations (CDMOs). Instead of solely depending on basic research grants, regional growth is driven by the swift advancement of antisense oligonucleotides and personalized messenger RNA (mRNA) candidates into late-stage clinical pipelines. This clinical progression is significantly supported by a well-established, high-density infrastructure comprising premier biopharmaceutical manufacturing hubs and a mature venture capital ecosystem that facilitates the rapid scaling of early-stage genomic platforms.
OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX
Within the current market framework, Danaher Corporation continues to anchor its position as the clear market leader, leveraging its extensive DNA/RNA portfolio—spanning rapid research-grade synthesis to high-volume cGMP supplies—to achieve unparalleled global scale. By deeply integrating its custom synthesis pipelines with corporate bioprocess automation and analytical instruments, the company delivers superior quality and rapid turnaround across diagnostics, therapeutics, and synthetic biology. Meanwhile, Maravai LifeSciences operates as a dynamic emerging leader, rapidly expanding its specialized cGMP oligo capacity and modified-nucleotide production footprint. Backed by its high-demand CleanCap mRNA capping technology and end-to-end CDMO services, Maravai remains uniquely positioned to capture late-stage clinical pipelines and advance directly into the market's leading quadrant.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Danaher Corporation (US)
- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Eurofins Scientific (Luxembourg)
- AstraZeneca (UK)
- LGC Limited (UK)
- Agilent Technologies, Inc. (US)
- Kaneka Corporation (Japan)
- Maravai LifeSciences (US)
- Biogen (US)
- Alnylam Pharmaceuticals, Inc. (US)
- Ionis Pharmaceuticals, Inc. (US)
- Novartis AG (Switzerland)
- Nippon Shinyaku, Co. Ltd. (Japan)
- Jazz Pharmaceuticals plc (Ireland)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 11.66 billion |
| Market Size in 2026 (Value) | USD 14.64 billion |
| Market Forecast in 2031 (Value) | USD 32.72 billion |
| Growth Rate | CAGR of 17.40% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: OLIGONUCLEOTIDE SYNTHESIS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| CDMO Vendor Evaluation & Selection Matrix | Systematic scoring of primary contract manufacturing providers based on active cGMP facility cleanrooms, regulatory compliance histories, and batch purification capacity | Accelerates the clinical outsourcing process while minimizing batch-to-batch consistency risks in volatile supply chains |
RECENT DEVELOPMENTS
- December 2025 : EnPlusOne Biosciences commercialized its proprietary enzymatic RNA synthesis platform, offering an alternative to traditional chemistry and enabling the reagent-free production of longer, modified RNA strands without legacy capping constraints.
- February 2025 : Astellas Pharma Inc. (Japan) announced that the US FDA approved expanded US Prescribing information for IZERVAY for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a result, IZERVAY was approved without a duration limit for dosing.
- September 2025 : WuXi STA officially opened its expanded large-scale oligonucleotide and peptide manufacturing facility, significantly ramping up midstream cGMP capacity to meet a surging pipeline of global commercial-phase antisense and siRNA drug contracts.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global oligonucleotide synthesis market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, the World Health Organization (WHO), the United States Food and Drug Administration (US FDA), the National Center for Biotechnology Information (NCBI), and regulatory body websites, among others. These sources also provided key information on major players, market classification and segmentation aligned with industry trends, regional and country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the oligonucleotide synthesis market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:
Oligonucleotide Synthesis Market : Top-Down and Bottom-Up Approach
Data Triangulation
After determining the overall market size through the estimation process, the total market was segmented into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.
Market Definition
Oligonucleotide synthesis is the chemical process of creating nucleic acid fragments with specific chemical structures or sequences, of varying sizes, to form a desired product. These fragments, known as oligonucleotides, have several applications in medical and life science research. They can be used for DNA sequencing and amplification, detecting complementary DNA or RNA through hybridization, creating artificial genes, and introducing targeted genetic mutations.
Oligonucleotides are also used to develop therapeutic drugs. These drugs are chemically synthesized and have different mechanisms of action, such as interfering with gene expression, blocking the production of harmful proteins, or restoring the function of mutated genes.
Key Stakeholders
- Pharmaceutical & biotechnology companies
- Hospitals
- Diagnostic laboratories
- Academic researchers and government research organizations
- Private research institutes
- Custom oligonucleotide service providers
- Contract manufacturing organizations (CMOs)
- Oligonucleotide equipment manufacturers
- Contract research organizations (CROs)
- Market research & consulting firms
- Venture capitalists
Report Objectives
- To define, describe, and forecast the global oligonucleotide synthesis market based on the offering, type, application, end user, therapeutic area, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oligonucleotide synthesis market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the oligonucleotide synthesis market
- To provide information on funding & investment activities, brand/product comparative analysis, vendor valuation, and financial metrics of the oligonucleotide synthesis market
Available customizations:
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix gives a detailed comparison of the product portfolios of the top five companies.
Geographical Analysis
- A further breakdown of the Rest of Europe’s oligonucleotide synthesis market into countries
- A further breakdown of the Rest of Asia Pacific’s oligonucleotide synthesis market into countries
- A further breakdown of the Rest of Latin America’s oligonucleotide synthesis market into countries
- A further breakdown of the Rest of Middle East’s oligonucleotide synthesis market into countries
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
- US Oligonucleotide Synthesis Market
- Canada Oligonucleotide Synthesis Market
- Germany Oligonucleotide Synthesis Market
- UK Oligonucleotide Synthesis Market
- France Oligonucleotide Synthesis Market
- Italy Oligonucleotide Synthesis Market
- Spain Oligonucleotide Synthesis Market
- China Oligonucleotide Synthesis Market
- Japan Oligonucleotide Synthesis Market
- India Oligonucleotide Synthesis Market
- Australia Oligonucleotide Synthesis Market
- South Korea Oligonucleotide Synthesis Market
- Brazil Oligonucleotide Synthesis Market
- Mexico Oligonucleotide Synthesis Market
- Argentina Oligonucleotide Synthesis Market
- Saudi Arabia Oligonucleotide Synthesis Market
- United Arab Emirates Oligonucleotide Synthesis Market
Growth opportunities and latent adjacency in Oligonucleotide Synthesis Market
Adam
Jul, 2026
I reviewed the Oligonucleotide Synthesis Market insights to better understand how custom synthesis demand is evolving across therapeutic development and large-scale genomic research programs..
Douglas
Jul, 2026
From a strategic planning perspective, the Oligonucleotide Synthesis Market analysis helped me evaluate how manufacturing scalability and regulatory expectations could influence long-term supplier partnerships..
Nathan
Jul, 2026
I found the breakdown of applications and technology adoption in the Oligonucleotide Synthesis Market particularly useful for assessing future investment opportunities in precision medicine and RNA-based therapeutics..